-
2024-512789-32-00
5
2017-10-09
Unresectable or metastatic soft tissue sarcoma
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2024-513964-24-00
5
2017-09-14
Squamous cell carcinoma, previously untreated
Stage III, stage IVa (op
-
2024-515119-23-00
9
2017-08-29
Phase Ib and Phase II part 1: HPV-16 positive recurrent or metastatic
-
2023-509671-17-00
5
2017-07-12
Breast Cancer
-
2024-510645-34-00
4
2017-06-28
RAS and B-RAF wild-type metastatic colorectal cancer.
RAS and B-RAF mu
-
2024-517489-41-00
5
2017-03-27
High-risk stage III colon cancer
-
2024-510704-37-00
5
2017-03-22
ER+/HER2- metastatic breast cancer
-
2024-513972-16-00
5
2017-01-30
- Resected tumors of sinuses or salivary glands
- Non-operable tumors
-
2024-513078-23-00
4
2016-12-02
breast cancer in young women
-
2024-515846-18-00
7
2016-09-19
Newly diagnosed Diffuse Large B Cell Lymphoma
-
2023-507889-89-00
5
2016-02-19
Respiratory tract infection
-
2023-505246-26-00
5
2016-01-27
High- or very-high risk, localized or locally advanced prostate cancer
-
2024-513079-42-00
5
2015-11-19
Intermediate-risk, high risk endometrial cancer
-
2024-518741-21-00
4
2014-12-23
colon cancer
-
2024-513455-33-00
4
2014-09-11
Bone sarcoma
-
2024-516198-61-00
5
2013-06-05
Patients with high risk of relapse, ER+ and HER2- primary non-metastat
-
2024-516996-34-00
5
2012-04-12
oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
-
2024-514844-10-00
4
2010-03-18
Retinoblastoma
-
2024-514756-32-00
5
2007-03-19
High grade osteosarcoma
-
2025-521503-43-00
4
2026-02-12
Atopic dermatitis
-
2024-518450-16-00
9
2025-06-13
Cardiogenic shock due to Acute Coronary Syndrome, cardiogenic shock of
-
2024-516687-28-00
5
2025-06-06
Patients with GPA and inadequate response to standard of care therapy
-
2023-510559-41-00
4
2025-01-02
Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck